Calithera Biosciences Top Management
Calithera Biosciences employs about 8 people. The company is managed by 8 executives with a total tenure of roughly 50 years, averaging almost 6.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Calithera Biosciences' management performance can provide insight into the company performance.
| Susan Molineaux CEO Co-Founder, CEO and President and Director |
| Stephanie Wong President Chief Accounting Officer, Vice President - Finance |
Calithera |
Calithera Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.5629) % which means that it has lost $0.5629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1414) %, meaning that it created substantial loss on money invested by shareholders. Calithera Biosciences' management efficiency ratios could be used to measure how well Calithera Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Calithera Biosciences Workforce Comparison
Calithera Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,390. Calithera Biosciences maintains roughly 8.0 in number of employees contributing less than 1% to equities under Health Care industry.
Calithera Biosciences Notable Stakeholders
A Calithera Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Calithera Biosciences often face trade-offs trying to please all of them. Calithera Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Calithera Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Susan Molineaux | Co-Founder, CEO and President and Director | Profile | |
| Stephanie Wong | Chief Accounting Officer, Vice President - Finance | Profile | |
| Eric Sjogren | Sr. VP of Drug Discovery | Profile | |
| Christopher Molineaux | Sr. VP of Devel. | Profile | |
| Allison Dillon | VP Strategy | Profile | |
| Susan Demo | VP Operations | Profile | |
| Frank Parlati | VP Research | Profile | |
| Emil MD | Chief Officer | Profile |
Calithera Biosciences Workforce Analysis
Traditionally, organizations such as Calithera Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Calithera Biosciences within its industry.Calithera Biosciences Manpower Efficiency
Return on Calithera Biosciences Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 5M | |
| Net Loss Per Executive | 5M | |
| Working Capital Per Employee | 2.4M | |
| Working Capital Per Executive | 2.4M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Calithera Pink Sheet
If you are still planning to invest in Calithera Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calithera Biosciences' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |